| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8192756 | ALMATICA | Gastric retained gabapentin dosage form |
Oct, 2022
(11 months ago) | |
| US8333992 | ALMATICA | Gastric retained gabapentin dosage form |
Oct, 2022
(11 months ago) | |
| US8252332 | ALMATICA | Gastric retained gabapentin dosage form |
Oct, 2022
(11 months ago) | |
| US7731989 | ALMATICA | Gastric retained gabapentin dosage form |
Oct, 2022
(11 months ago) | |
| US7438927 | ALMATICA | Methods of treatment using a gastric retained gabapentin dosage |
Feb, 2024
(4 months from now) | |
Gralise is owned by Almatica.
Gralise contains Gabapentin.
Gralise has a total of 5 drug patents out of which 4 drug patents have expired.
Expired drug patents of Gralise are:
- US8192756
- US8333992
- US8252332
- US7731989
Gralise was authorised for market use on 28 January, 2011.
Gralise is available in tablet;oral dosage forms.
Gralise can be used as treatment with gabapentin, including treatment of neuropathic pain, including neuropathic pain associated with postherpetic neuralgia.
The generics of Gralise are possible to be released after 26 February, 2024.
Drugs and Companies using GABAPENTIN ingredient
Market Authorisation Date: 28 January, 2011
Treatment: Treatment with gabapentin, including treatment of neuropathic pain, including neuropathic pain associated with postherpetic neuralgia
Dosage: TABLET;ORAL
GRALISE family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic